| 1 |
34589134 | Therapeutic Mechanism of Lapatinib Combined with Sulforaphane on Gastric Cancer. | 2021 |
2 |
| 2 |
25157953 | HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. | 2015 Apr 1 |
1 |
| 3 |
25449780 | Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib. | 2015 Jan 28 |
1 |
| 4 |
24820961 | A dual tyrosine kinase inhibitor lapatinib suppresses overexpression of matrix metallopeptidase 1 (MMP1) in endometrial cancer. | 2014 Sep |
3 |
| 5 |
23531216 | MEK inhibition increases lapatinib sensitivity via modulation of FOXM1. | 2013 |
2 |
| 6 |
24068620 | Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation. | 2013 Dec |
1 |
| 7 |
21499301 | Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. | 2011 Sep 29 |
1 |
| 8 |
20088787 | Ras-induced resistance to lapatinib is overcome by MEK inhibition. | 2010 Mar |
1 |